Author:
Kairemo Kalevi,Kangasmäki Aki
Publisher
Springer Berlin Heidelberg
Reference24 articles.
1. Bakker WH, Breeman WA, Kwekkeboom DJ et al (2006) Practical aspects of peptide receptor radionuclide therapy with [177Lu][DOTA0, Tyr3]octreotate. Q J Nucl Med Mol Imaging 50:265–271
2. Bodei L, Cremonesi M, Ferrari M et al (2008) Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATATE: the role of associated risk factors. Eur J Nucl Med Mol Imaging 35:1847–1856
3. Bodei L, Cremonesi M, Grana CM et al (2011) Peptide receptor radionuclide therapy with (177)Lu-DOTATATE: the IEO phase I-II study. Eur J Nucl Med Mol Imaging 38(12):2125–2135 epub Sept 3
4. Cremonesi M, Ferrari M, Bodei L et al (2006) Dosimetry in peptide radionuclide receptor therapy: a review. J Nucl Med 47:1467–1475
5. Cremonesi M, Ferrari M, Di Dia A et al (2011) Recent issues on dosimetry and radiobiology for peptide receptor radionuclide therapy. Q J Nucl Med Mol Imaging 55:155–167
Cited by
16 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献